Abstract:BackgroundBombesin Receptor Subtype-3 (BRS-3, Bombesin-like receptor, BB3) is an orphan G-protein coupled receptor (GPCR). Recent studies have shown that BRS-3 played a vital role in glucose regulation, insulin secretion, and energy homeostasis. Therefore, discovering more novel exogenous ligands with diverse structures for BRS-3 will be of great importance for target validation and drug development.PurposeIn this study, we aim to discover new agonists of BRS-3 from our natural compound libraries, providing a new probe to study the function of BRS-3.Study designMultiple cell-based assays and in vivo experiments were performed to identify the new ligand.MethodsBRS-3 overexpression cells were coupled with FLIPR assay, homogeneous time-resolved fluorescence (HTRF) IP-ONE assay, dynamic mass redistribution (DMR) assay, β-arrestin2 recruitment assay, and western blot to determine receptor activation and downstream signaling events. To further validate the target of BRS-3, a series of in vitro and in vivo experiences were conducted, including glucose uptake, glucose transporter type 4 (GLUT4) transportation in C2C12, and oral glucose tolerance test (OGTT) in mice.ResultsWe discovered and identified oridonin as a novel small molecule agonist of BRS-3, with a moderate affinity (EC50 of 2.236 × 10−7 M in calcium mobilization assay), specificity, and subtype selectivity. Further in vitro and in vivo tests demonstrated that oridonin exerted beneficial effects in glucose homeostasis through activating BRS-3.ConclusionsOridonin, as the discovered new ligand of BRS-3, provides a valuable tool compound to investigate BRS-3′s function, especially for target validation in type 2 diabetes and obesity. Oridonin is promising as a lead compound in the treatment of metabolic disorders. Compared to the known agonists of BRS-3, we can take advantage of the multiple reported pharmacological activities of ODN as a natural product and assess whether these pharmacological activities are regulated by BRS-3. This may facilitate the discovery of novel functions of BRS-3.

Structural and functional characterization of the endogenous agonist for orphan receptor GPR3

Cryo-EM structures of orphan GPR21 signaling complexes

Lipid-Dependent Activation of the Orphan G Protein-Coupled Receptor, GPR3

Structural basis of ligand recognition and self-activation of orphan GPR52

Structure of GPR101–Gs enables identification of ligands with rejuvenating potential

The activation mechanism and antibody binding mode for orphan GPR20

Structure basis of ligand recognition and activation of GPR55

Dynamic Insights into the Self-Activation Pathway and Allosteric Regulation of the Orphan G-Protein-Coupled Receptor GPR52

Identification of the orphan GPR25 as a receptor of the chemokine CXCL17

Exploring the constitutive activation mechanism of the class A orphan GPR20

GPR39: An orphan receptor begging for ligands

Spatiotemporal Control of GPR37 Signaling and Its Behavioral Effects by Optogenetics

A homology modeling study toward the understanding of three-dimensional structure and putative pharmacological profile of the G-protein coupled receptor GPR55.

Reevaluating GPR30: A Paradigm Shift from Estrogen Receptor to Unique Hydrophilic Ligand Activation

Discovery of oridonin as a novel agonist for BRS-3

Molecular mechanism of agonism and inverse agonism in ghrelin receptor

Research Status of the Orphan G Protein Coupled Receptor 158 and Future Perspectives

Molecular Mechanism of Action of GPR91 Agonists and Antagonists: Insights from Molecular Dynamics Simulation

Identification of oleic acid as an endogenous ligand of GPR3 Corrections

The Pathophysiological Functions and Therapeutic Potential of GPR39: Focus on Agonists and Antagonists

Discovery and Characterization of Novel Antagonists of the Proinflammatory Orphan Receptor GPR84